Table 2.
HDAC inhibitors in developmental phases.
| Drug | Therapeutic use | Developmental stage |
|---|---|---|
| (1) Panobinostat | Cutaneous T-cell lymphoma | Phase 3 |
|
| ||
| (2) Valproic acid | Cervical cancer | Phase 3 |
| Ovarian cancer | Phase 3 | |
|
| ||
| (3) Belinostat | Ovarian cancer | Phase 2 |
|
| ||
| (4) Mocetinostat | Follicular lymphoma | Phase 2 |
| Hodgkin's lymphoma | Phase 2 | |
| Acute myeloid leukemia | Phase 2 | |
|
| ||
| (5) Abexinostat | Sarcoma and lymphoma | Phase 2 |
|
| ||
| (6) Entinostat | Hodgkin's lymphoma | Phase 2 |
| Breast cancer | Phase 2 | |
| Metastatic lung cancer | Phase 2 | |
|
| ||
| (7) SB939 | Prostate cancer | Phase 2 |
|
| ||
| (8) Resminostat | Hodgkin's lymphoma | Phase 2 |
| Hepatocellular carcinoma | Phase 2 | |
|
| ||
| (9) Givinostat | Leukemia and lymphoma | Phase 2 |
| Myelofibrosis | Preclinical | |
|
| ||
| (10) Kevetrin | Ovarian cancer | Phase 1 |
|
| ||
| (11) ACY-1215 | Multiple myeloma | Phase 1 |